The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to the Securities and Exchange Commission (SEC)
by insider Hayden Brian J since year 2005.
The trader's CIK number is 1262224.
At the time of this reporting, Hayden Brian J is the SVP, Chief Financial Officer of Savient Pharmaceuticals Inc .
(stock ticker symbol SVNT).
See this page for all insider trading activities at Savient Pharmaceuticals Inc .
Stock purchases, sales, and option exercises reported by insider Hayden Brian J since 2005.
Trade Date
Symbol
Company Name (Issuer)
Trade Type
Shares
Price ($)
Value ($)
2008-05-06
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
24.00
120,000
2008-02-28
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
24.06
120,295
2008-02-29
SVNT
Savient Pharmaceuticals Inc
Sale
2,279
24.00
54,696
2008-02-15
SVNT
Savient Pharmaceuticals Inc
Sale
2,817
19.98
56,279
2008-01-02
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
5.33
26,650
2008-01-02
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
23.47
117,360
2008-01-03
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
24.26
121,286
2007-12-18
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
5.33
26,650
2007-12-18
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
20.09
100,440
2007-12-17
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
5.33
26,650
2007-12-17
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
19.91
99,537
2007-12-13
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
5.33
26,650
2007-12-14
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
5.33
26,650
2007-12-13
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
17.18
85,893
2007-12-14
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
17.12
85,596
2007-03-05
SVNT
Savient Pharmaceuticals Inc
Sale
4,450
12.52
55,714
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Hayden Brian J
(SVP, Chief Financial Officer of Savient Pharmaceuticals Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.
